AN2 Therapeutics, Inc. (ANTX)
Nasdaq: ANTX · Pharmaceutical Preparations · Menlo Park, CA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Mar 17, 2026 | Mar 25, 2025 | Mar 29, 2024 | Mar 29, 2023 | · |
| Research and development | 24,769 | 40,488 | 54,871 | 28,511 | 16,156 |
| General and administrative | 13,340 | 14,066 | 14,764 | 12,751 | 4,668 |
| Total operating expenses | 38,109 | 56,788 | 69,635 | 42,262 | 21,574 |
| Operating income | -38,109 | -56,788 | -69,635 | -42,262 | -21,574 |
| Interest and investment income | 2,934 | 5,466r | 4,860 | 1,351 | 69 |
| Other income (expense), net | 1 | 1 | 43r | 1,306r | -38 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income including non-controlling interests | -35,174 | -51,321 | -64,732 | -40,956 | -21,543 |
| Net income | -35,174 | -51,321 | -64,732 | -40,956 | -21,543 |
| Net income to common shareholders | -35,174 | -51,321 | -64,732 | -42,776 | -28,058 |
| Earnings per share, basic | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
| Earnings per share, diluted | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
| Weighted average shares, basic | 30,215,747 | 29,828,227 | 23,600,107 | 15,340,134 | 2,638,197 |
| Weighted average shares, diluted | 30,215,747 | 29,828,227 | 23,600,107 | 15,340,134 | 2,638,197 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterest
us-gaap:InvestmentIncomeNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding